ARTICLE | Clinical News
CERC-501: Ph II data
December 21, 2016 1:00 AM UTC
Top-line data from a double-blind, 2-way crossover, U.S. Phase II trial in 71 heavy smokers who are not seeking treatment for tobacco use disorder showed that once-daily 15 mg CERC-501 for 8 days miss...
BCIQ Target Profiles